approach for all patients. Furthermore, the mechanisms which underlie clinical efficacy of proven claudication treatments remain uncertain.
Stem cell therapies have been proposed as a potential treatment option due to their presumed angiogenicity, associated with improvements in tissue oxygenation and ischemic muscle perfusion. 2, 3 However, the question of whether the stimulation of collateral blood vessel growth or modification of existing arteries remains in the causal pathway remains unclear.
Magnetic resonance imaging (MRI) can assess arterial anatomy using contrast-enhanced magnetic resonance angiography (MRA). In addition, MRI has the ability to measure muscle perfusion and vascular reactivity. 4 Inasmuch as MRI uniquely provides both anatomic and physiologic data, the CCTRN chose MRI imaging end points for 3 of its 4 primary end points in the PACE clinical trial. Those end points include the change from baseline to 6 months in (1) total collateral count (thigh and calf) from MRA, (2) calf muscle plasma volume (capillary perfusion) as measured by dynamic contrast-enhanced MRI (DCE-MRI), and (3) peak hyperemic popliteal flow by PC-MRI. This article describes the method of their MRI-based determination and assesses the relationship between these MRI measurements in patients with and without PAD.
Methods/design
The CCTRN PACE is a randomized, double-blind, placebo-controlled clinical trial designed to assess the clinical safety and efficacy of autologous bone marrowderived ALDH br cells delivered by direct intramuscular injections in patients with PAD and limiting claudication symptoms. Funding for PACE was provided to the CCTRN by the National Heart, Lung, and Blood Institute at the National Institutes of Health. The authors are solely responsible for the design and conduct of this trial, all trial analyses, the drafting and editing of the manuscript, and its final contents. The detailed study design, including the inclusion and exclusion criteria, sample size, and outcomes have been previously published. 5 Primary study outcomes include both clinical end point (change in peak walking time) and physiologic MRI-derived measurements of leg collateral arterial anatomy, arterial blood flow, and capillary perfusion at 6 months compared with baseline. 5 
MRI protocol design and analysis
As shown in protocol operations flowchart (Figure 1 ), patient preparation included intravenous access for MRI contrast agent injection, placement of cuffs for inducing reactive hyperemia, and positioning of the MRI coils for signal reception. Gadopentate dimeglumine (Magnevist (gadopentetate dimeglumine, Bayer Schein Pharma, Germany)) was chosen as the contrast agent due to its availability at all study sites.
All image postprocessing and data analyses were performed at the core lab (Johns Hopkins University, Baltimore, MD). All site personnel were trained in implementation of the imaging protocol and proper handling of clinical trial data. The technologists were required to undergo on-site training and participate in an online webinar before site certification. For each study, a detailed check for image quality and usability was performed and appropriate feedback conveyed to the technologists. Table I provides a list of the scanner types, magnet strength, and coil availability at each site.
Calf muscle reactive hyperemia. A customized MRI-compatible thigh blood pressure cuff (Magmedix Inc, Fitchburg, MA) was used for thigh arterial occlusion of the index leg, by cuff inflation to the "occlusion" pressure for 5 minutes, to induce calf skeletal muscle ischemia. The lowest thigh cuff pressure, causing complete arterial occlusion demonstrated by abolition of pedal artery flow seen on a Doppler probe, was identified as the occlusion pressure to minimize subject discomfort during the MRI. 6 
Localizers
Magnetic resonance imaging started with the acquisition of multiplanar scout images covering the upper and lower legs and was followed by 2-dimensional (2D) time-of-flight imaging to obtain low-resolution images of the underlying arterial anatomy.
Dynamic contrast-enhanced MRI
The thickest portion of the calf was identified from the prior acquired sagittal scout and 3-dimensional (3D) reconstructed time-of-flight images. Tissue spin-lattice relaxation time (T1) maps of 8 transverse slices centered at the thickest portion of the calf were calculated using a multiple flip-angle method with same positioning and imaging parameters for the DCE-MRI sequence but with varying flip angles of 5°, 8°, 12°, and 15°. 7 The DCE-MRI data acquisition of the calf was performed with a spoiled fast gradient echo sequence and a flip angle of 15°: slice thickness of 5 mm, slice gap of 1 mm, in-plane acquired spatial resolution of 1 mm × 1 mm, repetition time/echo time (TR/TE) of~2.5 ms/1 ms, and parallel imaging factor of 2. This yielded a temporal resolution of approximately 3 to 4 second per dynamic, and the continuous acquisition of 100 dynamics results in a scan time of 5 to 6 minutes. The cuff was inflated to the occlusion pressure, and then a 0.05-mmol/kg dose of gadolinium (followed by 1 mL of saline flush) was administered at the rate of 1.5 cc/s. The contrast agent pooled in the arteries above the inflated cuff for 5 minutes as hyperemia was induced in the calf muscle. The DCE-MRI sequence was started 20 seconds before the cuff deflation and continued to run as the cuff rapidly deflated. The DCE-MRI images were analyzed using the DCE Tool plugin (http://kyungs.bol.ucla.edu/software/ DCE_tool/DCE_tool.html) in Osirix (Figure 2 ).
An affine registration algorithm with conjugate gradient minimization of the mutual information between the reference (flip-angle 15°images from multiple flip-angle imaging) and moving images (DCE images) was used for registering the images 8 in MATLAB (Mathworks, Natick, MA). After estimation of the T1 map, the observed signal intensities on the DCE images were converted to contrast agent concentrations. An arterial input function (AIF) was drawn corresponding to the most prominent artery visually identified by the user. Failing the identification of a prominent artery, a population-averaged AIF was used. 9 The user manually placed regions of interest in the anterior tibial, gastrocnemius, and soleus muscles resulting in 3 volumes of 1 cm 3 each. Quantitative analysis using a modified Tofts' model yielded the transfer constant from the blood plasma to the extracellular extravascular space (Ktrans) and the whole blood plasma volume per unit of tissue (Vp). 10 Change within 6 months in calf muscle plasma volume (a measure of capillary perfusion) was a primary end point of the PACE trial.
Phase-contrast MRI
Two-dimensional PC-MRI of the popliteal artery with electrocardiographic gating was performed with the following acquisition parameters: spatial resolution 1.2 mm × 1.2 mm, slice thickness 5 mm, TR/TE~10 ms/2.2 ms, flip angle 25°, parallel imaging factor 2, velocity encoding of 100 cm/s (increased by 50 cm/s if aliasing observed), and time of acquisition per scan 30-40 seconds. The prescribed imaging plane was perpendicular to the long axis of the popliteal (Figure 3) .
The protocol acquired 3 PC-MRI dynamics before cuff compression to estimate baseline blood flow as well as its short-term variability. Phase-contrast MRI acquisitions were then performed consecutively for 10 minutes from the start of cuff deflation. Flow curves were generated using QFlow (v5.2; Medis, Leiden, the Netherlands) following a methodology described previously. 11 From the generated flow curve, the peak instantaneous cardiac blood flow (characterized for each dynamic) within that cardiac cycle was noted. Measured parameters included resting flow (average peak flow at rest for 3 acquisitions), peak hyperemic popliteal flow (peak flow after cuff deflation as observed for 10 minutes), time-to-peak hyperemic flow (from the point of cuff deflation), and arterial flow reserve (peak hyperemic flow − resting flow). Change within 6 months in peak hyperemic popliteal flow is a primary end point of the PACE trial. Protocol flowchart including the gadolinium-dimeglumine contrast dose and reactive hyperemia cuff compression technique. Survey included localizers and 2D time-of-flight sequences as these images were used for planning and positioning of future data acquisition. T1 mapping used a multiple flip-angle method as an essential component of accurate perfusion measurement. DCE-MRI was performed using fast gradient echo sequences to enable measurement of capillary perfusion by calf muscle plasma volume after cuff-induced hyperemia. 2D PC-MRI measured the flow through the popliteal artery at both rest and hyperemic state to enable measurement of vascular reactivity. Contrast-enhanced MRAs of the upper and lower legs were performed separately using time-resolved angiographic sequences to assess stenosis and collateral artery anatomy.
Contrast-enhanced MRA
Contrast-enhanced MRA of the thigh and the calf were performed separately with an overlap in the volume of interest to ensure complete coverage of the lower extremity arteries from the bifurcation of the common femoral artery to the pedal arteries.
Thigh MRA. A 3D spoiled gradient echo sequence was used to obtain 1 precontrast and 3 postcontrast MRA scans of the thigh using the following parameters: 1.3 mm × 1 mm × 1.3 mm spatial resolution, TR/TE~2.5/1 ms, a parallel imaging factor 2, and a time of acquisition per sequencẽ 15-22 seconds. The volume of interest in the thigh spanned the bifurcation of the femoral artery to the trifurcation of the popliteal artery ( Figure 4) .
After a 0.1-mmol/kg dose of gadolinium (followed by 10 mL of saline) was injected at the rate of 1.5 cc/s, fluoroscopic triggering was used to initiate the postcontrast scans.
Calf MRA. Time-resolved MRA via an ultrafast high--resolution 3D dynamic scan was used to assess calf blood flow kinetics with acquisition parameters: isotropic spatial resolution~1 mm × 1 mm × 1 mm, 25°flip angle, TR/TE~3 ms/1 ms, a parallel imaging factor 2, and vendor specific undersampling methods (TWIST in Siemens (Simens Medical Systems, Erlangen, Germany), TRICKS in GE (General Electric, Waukesha, WI), and Keyhole/4D TRAK in Philips (Philips Medical Systems, Best, the Netherlands)) to obtain a temporal resolution of 8-12 seconds per dynamic. The volume of interest in the calf spanned the region from the trifurcation of the popliteal artery to the pedal arteries ( Figure 5) .
A single precontrast acquisition was performed, and then a 0.05-mmol/kg dose of gadolinium was administered at a rate of 1.5 cc/s followed by 10 mL of saline flush. Simultaneous to contrast injection, the postcontrast MRA acquisitions were started and continued for 2 minutes.
MRA image analysis. The degree of arterial vascularization was assessed manually by quantifying the average number of conduit, collateral, and terminal branch arteries crossing 5 transverse planes in the thigh (a reference plane at the highest-grade stenosis, 3 proximal and 1 distal to it) 5 cm apart, using the dynamic scans that depicted the arteries with the highest contrast-to-noise ratio via visual inspection 4, 13, 14 ( Figure 6 ). The extent of arterial collateralization at the thigh and calf was measured by quantifying the number of vessels that bypassed a stenosis and reconstituted the main conduit vessel (Figures 4 and 5) . In addition, the number and the degree of stenosis in the thigh and calf arteries were measured. At the thigh, the superficial femoral artery was divided along its length into 3 equal segments with the degree of stenosis measured and reported for the tightest lesion in each segment. At the calf, the tightest stenosis in each of the anterior tibial, the posterior tibial, and the peroneal artery was measured and reported. All MRA images were reviewed on a dedicated workstation (AZE Technologies, Tokyo, Japan). The change within 6 months in the total collateral count measured at the thigh and at the calf is a primary end point of the PACE trial.
Population
Eighty-two participants with PAD were recruited across 9 sites over a period of 30 months (June 2013 to December 2015), and randomized 1:1 to the treatment or placebo groups. All PAD participants had symptoms of intermittent claudication, a significant stenosis or occlusion of infrainguinal arteries, and a resting ankle-brachial index less than 0.90 or resting toe-brachial index of less than 0.70. Subjects with critical limb ischemia or a contraindication to MRI were excluded. Sixteen participants from 8 clinical sites (1-3 studies per site) were evaluated for the PACE MRI reproducibility substudy. All measures were analyzed by 2 experienced analysts blinded to each other's analysis for interreader reproducibility assessment. These parameters were then measured a second time by one of the analysts blinded to the first interpretation and at least 2 weeks apart to assess intrareader reproducibility.
Test-retest reproducibility was performed at 1.5 T (Siemens Avanto) and 3 T (Siemens Trio) scanners in 16 men and women (8 at 1.5 T and 8 at 3 T) at Johns Hopkins University, Baltimore, MD, without a prior diagnosis of PAD (based on self-reported questionnaires) recruited from the community to serve as normal control participants for comparison of MRI measures. The entire protocol was performed twice-at baseline and a repeat scan 1 month later (average 32 ± 5 days). All parameters were measured by one experienced reader who was blinded to the baseline read when assessing the repeat scan.
Both protocols were approved by the institutional review boards of participating organizations, and all participants signed informed consent.
Statistical analysis
The interclass correlation coefficient (ICC) was used to measure the agreement between the reads for continuous variables, and the κ concordance test was used for categorical variables. A 2-sample t test was used to determine the significance of differences in the functional parameters between PAD and healthy participants for 
Results

Reproducibility assessment
One of the primary end points of PACE-capillary perfusion measured by calf muscle plasma volume (Vp)-demonstrated good-to-excellent interreader and intrareader reproducibility (ICC range 0.78-0.90). Phase--contrast MRI measures also demonstrated excellent An axial image of a transversal slice of the calf muscle from DCE-MRI and the corresponding enhancement graph for the index leg (right leg). The red region of interest indicates the pixels used to obtain the arterial-input function, and the other regions of interest indicate delineated skeletal muscle regions.
Figure 3
Two-dimensional PC-MRI images (left) using the cuff paradigm before. The graph on the right shows the peak hyperemic popliteal flow measured in a normal volunteer (blue curve) and a patient with significant stenosis of the popliteal artery (red) up to 8 minutes after cuff release. The cuff was inflated to suprasystolic pressures for 5 minutes in both cases.
interreader and intrareader reproducibility, including the primary end point-peak hyperemic popliteal flow (ICC 0.95) and other measures of PC-MRI assessed in the index leg (ie, resting flow, arterial flow reserve, and time-to-peak flow after cuff deflation; ICC range 0.71-0.98). Table II shows the mean values and ICCs for each parameter.
The third primary MRI end point, the total collateral count at the thigh and calf, also demonstrated high reproducibility (Table III) .
The measurements of 2 of the PACE MRI end points, capillary perfusion measured by calf muscle plasma volume and peak hyperemic popliteal flow, as well as other PACE measures (Ktrans, resting flow, and arterial flow reserve) using DCE-MRI and PC-MRI demonstrated good-to-excellent test-retest reproducibility with a small ICC (range 0.73-0.94) as shown in Table IV .
Neither arterial stenoses nor occlusions were observed in the normal volunteers in the thigh or calf muscles. Test-retest reproducibility was moderate to good for the quantification of number of arteries per plane.
Peripheral artery disease vs healthy participants
The PAD patients in our study were significantly older than the healthy group (Table V) .
In 4 of the 82 PAD participants, an AIF was not recognized, and hence, a population-averaged AIF was used. Capillary perfusion measured by calf muscle plasma volume (Vp) and Ktrans were significantly higher in the healthy group as compared with the patients (Figure 7 ).
The differences remained significant after adjustment for age, gender, and scanner magnetic field strength. The resting flow, peak hyperemic popliteal flow, and arterial flow reserve were higher, but the time-to-peak flow after cuff deflation was lower, for healthy participants compared with PAD participants. In 5 of the PAD participants, there was complete occlusion of the popliteal artery, and hence, all flow measures were characterized as 0 mL/s and time-to-peak flow was not calculated. The number of arteries per plane at the point of occlusion in the thigh for PAD patients was not significantly different from the number of arteries per plane characterized at the thigh level in the healthy participants. Although no collateralization was observed in the healthy participants, there was significant collateralization observed in the PAD participants (thigh: 3.6 ± 3.3, calf: 1.1 ± 2; total: 4.7 ± 4.0 [mean ± SD]).
Discussion
The PACE clinical trial was designed to evaluate the utility of a series of potentially important but novel PAD-specific MRI end points. The primary MRI end points of the study were chosen to assess change within 6 months in the total collateral count (calf and thigh), capillary perfusion measured by calf muscle plasma volume, and peak hyperemic popliteal flow. Theoretically, these calf muscle MRI measurements may provide important new objective PAD anatomic and physiologic data that could define the potential efficacy of this cell-based investigational intervention. The results of the preliminary work described here demonstrated goodto-excellent reproducibility for the MRI end points chosen for PACE. In addition, capillary perfusion measured by calf muscle plasma volume and peak hyperemic popliteal flow were lower in the PACE participants at baseline than in healthy, whereas the PACE participants showed a high degree of collateralization. The ability of MRI measurements to provide objective evidence of new cell-mediated collateral growth fulfilled a key PACE trial objective.
Peripheral artery disease clinical trials designed to collect baseline and posttreatment MRI data confront key challenges associated with the implementation of complex imaging protocol in a multicenter setting. We identified several challenges in implementing a uniform imaging protocol across the participating sites: (1) varying field strengths (1.5 and 3.0 T) have differential effects on the observed signal-to-noise ratios and susceptibility to artifacts; (2) variations in gradient performance and peak transmit radiofrequency amplitude across sites may limit the ability to adjust certain imaging parameters; (3) vendors may vary on undersampling strategies and parallel imaging techniques; and (4) centers may use different MRI contrast agents leading to different contrast agent relaxivities, binding mechanisms, and biological clearance times affecting imaging. 12 The present study created site qualification standards, continuous quality assurance efforts, and a standardized image acquisition process to ensure reliability and comparability, and demonstrated that all of the end points had moderate to excellent intrareader and interreader reproducibility as well as moderate to high test-retest reproducibility. Magnetic resonance imaging also has been used to measure angiogenesis during evaluation of tumors using T1-weighted DCE-MRI perfusion imaging. 15, 16 Dynamic contrast-enhanced MRI is a technique to quantify microcirculation to measure the rate of vascular reactivity and capillary perfusion. 17, 18 These measures showed the ability to discriminate between PAD and healthy participants, especially in hyperemic conditions. 7, 12, [19] [20] [21] Indeed, similar to previous studies, we found that there was a significant difference between PAD and healthy participants in both capillary perfusion measured by calf muscle plasma volume and the transfer constant also showing high reproducibility. Identification of a predefined plane for acquisition of the AIF located proximal to the imaging plane is complicated by the possibility of there being an occlusion or even a partial stenosis of the arterial wall changing flow characteristics. To minimize these effects and to make implementation of the protocol easier across sites, measurement of AIF was performed at the same slice. Arterial flow reserve might provide additional diagnostic and physiologic data as compared with measurements of resting leg blood flow alone, and have shown high reproducibility. 11, 22 Similar to previous demonstrations, 11 we showed that both resting flow and peak hyperemic popliteal flow were lower in PAD participants compared with healthy participants, indicative of decreased arterial flow reserve in the PAD population. The time-to-peak flow after cuff release (deflation), as demonstrated earlier, was higher in PAD participants, indicative of decreased maximal arteriolar vasodilation.
Study limitations
This study evaluated the test-retest reproducibility in healthy participants to decrease the risk of repeated administration of gadolinium in individuals with PAD. It is possible that these reproducibility data would be different in older and less healthy individuals with PAD. Similarly, the sample size of this reproducibility study is small, although it is comparable to other MRI reproducibility studies. 4, 20 Furthermore, 9 sites were used in this clinical trial and achievement of comparable quality assurance may prove to be more challenging with a higher number of study sites in larger studies. Also, the healthy participants in this study were younger than the PAD patients. We minimized this effect by adjustments for age and gender in our comparisons; however, this may not be ideal. Finally, MRI was used to evaluate leg PAD anatomy, popliteal artery blood flow, and calf perfusion; however, it remains possible that these variables do not represent the key mechanisms that underpin claudication physiology. Other potentially important measures, such as skeletal muscle innervation, conditioning, muscle cytochrome oxidative metabolism, and other factors are not measured by these techniques. No comparisons were made with computed tomography, ultrasound, or invasive angiography; therefore, extension to other imaging modalities may not be straightforward.
Conclusion
An advanced MRI protocol and associated analytic methodology, supported by a core laboratory, can provide reproducible, high-fidelity data to accurately measure PAD native artery anatomy and disease severity, Primary endpoints highlighted * Ktrans = Influx constant of skeletal muscle from dynamic contrast-enhanced MRI. † n = 80 ‡ Arterial flow reserve = peak hyperemicpoplitealflow -resting flow. § n = 75
ll Normalized arterial flow reserve = (peak hyperemic popliteal flow -resting flow) /resting flow.
total collateral count, peak hyperemic popliteal flow, and capillary perfusion measured by calf muscle plasma volume. These methods were reproducible and differentiated between PAD and healthy participants. These measurements in individuals with PAD at baseline and after stem cell administration, within a prospective, placebo-controlled, multicenter clinical trial (PACE) will evaluate the hypothesis that stem cell administration may benefit calf muscle perfusion and associated clinical PAD symptoms.
